1	Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar		
2	Fidisoa Rasambainarivo <sup>1,2</sup> , Tanjona Ramiadantsoa <sup>3,4,5</sup> , Antso Raherinandrasana <sup>6,7</sup> , Santatra		
3	Randrianarisoa <sup>2</sup> , Benjamin L. Rice <sup>1,8</sup> , Michelle V. Evans <sup>5</sup> , Benjamin Roche <sup>5</sup> , Fidiniaina Mamy		
4	Randriatsarafara <sup>7,9</sup> , Amy Wesolowski <sup>10</sup> and C. Jessica Metcalf <sup>1,11</sup> .		
5			
6	1. Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ,		
7	USA		
8	2. Mahaliana Labs SARL, Antananarivo, Madagascar		
9	3. Department of Life Science, University of Fianarantsoa, Madagascar		
10	4. Department of Mathematics, University of Fianarantsoa, Madagascar		
11	5. MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France		
12	6. Surveillance Unit, Ministry of Health of Madagascar		
13	7. Faculty of Medicine, University of Antananarivo		
14	8. Madagascar Health and Environmental Research (MAHERY), Maroantsetra,		
15	Madagascar		
16	9. Direction of preventive Medicine, Ministry of Health of Madagascar		
17	10. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,		
18	Baltimore, MD, USA		
19	11. Princeton School of Public and International Affairs, Princeton University, NJ, USA		
20	Abstract		
21	Background: While mass COVID-19 vaccination programs are underway in high-income		
22	countries, limited availability of doses has resulted in few vaccines administered in low and		
23	middle income countries (LMICs). The COVID-19 Vaccines Global Access (COVAX) is a WHO-		
24	led initiative to promote vaccine access equity to LMICs and is providing many of the doses		

available in these settings. However, initial doses are limited and countries, such as
Madagascar, need to develop prioritization schemes to maximize the benefits of vaccination
with very limited supplies. There is some consensus that dose deployment should initially target
health care workers, and those who are more vulnerable including older individuals. However,
questions of geographic deployment remain, in particular associated with limits around vaccine
access and delivery capacity in underserved communities, for example in rural areas that may
also include substantial proportions of the population.

32

33 Methods: To address these questions, we developed a mathematical model of SARS-CoV-2

34 transmission dynamics and simulated various vaccination allocation strategies for Madagascar.

35 Simulated strategies were based on a number of possible geographical prioritization schemes,

36 testing sensitivity to initial susceptibility in the population, and evaluating the potential of tests for

37 previous infection.

38

39 Results: Using cumulative deaths due to COVID-19 as the main outcome of interest, our results 40 indicate that distributing the number of vaccine doses according to the number of elderly living 41 in the region or according to the population size results in a greater reduction of mortality 42 compared to distributing doses based on the reported number of cases and deaths. The 43 benefits of vaccination strategies are diminished if the burden (and thus accumulated immunity) 44 has been greatest in the most populous regions, but the overall strategy ranking remains 45 comparable. If rapid tests for prior immunity may be swiftly and effectively delivered, there is 46 potential for considerable gain in mortality averted, but considering delivery limitations 47 modulates this.

48

49 Conclusion: At a subnational scale, our results support the strategy adopted by the COVAX50 initiative at a global scale.

### 51 Introduction

52 The COVID-19 pandemic has resulted in a global health crisis resulting in an estimated 198 53 million cases and 4.2 million deaths (as of 31 July 2021) globally [1]. Until recently, non-54 pharmaceutical interventions, including social distancing, mask wearing, and travel restrictions 55 were the primary mitigation measures. However, the development, approval, and distribution of 56 several highly effective COVID-19 vaccines has resulted in a new era of public health response. 57 The overall impact of mass vaccination on the global pandemic will depend on access to 58 vaccines and ability to rapidly vaccinate populations [2]. There has been global competition to 59 procure COVID-19 vaccines, and many low and middle income countries (LMICs) have been 60 less successful than richer countries in securing vaccines [3] despite the COVAX initiative. 61 COVAX is a World Health Organization (WHO) led initiative to promote vaccine access equity to 62 LMICs and is set up to provide enough doses to immunize 20% of the population through 63 distribution of multiple smaller batches [4]. Such efforts have provided essential baseline doses 64 to LMICs, but even with vaccines in hand, countries face a number of logistical challenges. 65 Some COVID-19 vaccines have extreme cold chain requirements and relatively short vaccine 66 shelf-life that adds difficulties in avoiding vaccine wastage [4]. Likewise, achieving equity in 67 vaccine coverage is always affected by heterogeneity in access to care [5] and may be further 68 complicated by vaccine hesitancy [6]. However, many LMICs have more recent experience with 69 mass vaccination campaigns (e.g., polio, measles) [7], which may provide an advantage in 70 implementation relative to wealthier settings where mass vaccination campaigns have been less 71 frequent in recent history.

72

Policy makers in LMICs face the central question of how COVID-19 vaccine doses should be
allocated among populations in the face of these constraints and considerations of burden. So
far, mathematical models developed to address the question of vaccine dose allocation have

76 predominantly focused on the tradeoffs between prioritizing younger high contact individuals 77 (which would reduce transmission) vs older high risk individuals (which would reduce mortality 78 on infection). Previous work suggests that priority should be given to healthcare workers (HCW) 79 and then to older adults, in line with rankings and guidelines provided by the WHO [8-10]. 80 However, it should also be considered that focusing on distribution across age may neglect 81 other drivers of inequity, such as geography and ethnicity [11]. For LMICs, a further important 82 issue is local availability of personnel who can deliver doses, as numbers of HCWs may be 83 limited.

84

85 Here, we explore the question of how regional vaccine dose distribution might be designed to 86 minimize the burden of COVID-19 in Madagascar in the light of these features. We leverage 87 data collected as part of a dashboard (www.covid19mg.org) that collates official reported cases 88 of COVID-19 and census information. To date, Madagascar has officially reported a total of x 89 cases and y deaths since March 20th 2020. Most cases (x) and deaths (y) are reported from the 90 capital region of Analamanga, also the most populated region in the country with approximately 91 3 620 000 people representing 14% of the population. However, there is considerable 92 uncertainty as to the burden of the disease on the Malagasy population to date, especially in 93 rural areas where reporting rates are likely to be low and limited access to testing [12]. As prior 94 infection by SARS-CoV-2 does generate immunity likely to be protective [13] against disease if 95 not reinfection [14, 15], subnational variation in the trajectory of the pandemic to this point could 96 influence the dose deployment strategy among regions that minimizes burden. However, 97 inevitable uncertainties call for a focus on vaccine deployment efforts that are robust in the face 98 of this underlying subnational variation rather than hinging on its characteristics. 99

On April 3rd 2021, Madagascar initiated the necessary steps to re-join COVAX and distributed
 the first doses of vaccines to healthcare workers and vulnerable populations on May 10th. As of

102 July 20th 2021, 197 000 doses of an initial batch comprising 250 000 ChAdOx1-nCOV 103 (Covishield<sup>™</sup>) vaccines were administered representing 0.73% of the national population 104 (ourworldindata.org). These doses were distributed between the 22 different regions based on 105 population size of each region. To inform the next steps in vaccine dose allocation strategies in 106 Madagascar, we synthesize data on the regional distribution of elderly population and the 107 number of reported cases and deaths in the country. Building from this background, we develop 108 a mathematical model to investigate the optimal vaccine deployment strategy in the context of 109 realistic constraints for mass vaccination campaigns based on health care worker availability, 110 and known features of the burden of infection over age. We contrast four possible strategies for 111 distribution based on a) population size, b) number of individuals over 60 years old, c) the 112 number of reported cases, and d) the number of COVID-19 deaths by region. These strategies 113 weigh different factors, i.e. those most at risk versus areas with the highest burden of the 114 disease, and allow for a comparison of implementable strategies by weighing the overall 115 number of deaths averted through each approach. Since deployment of vaccines to areas that 116 had experienced large-scale outbreaks in the first waves of the infection might be less beneficial 117 than deployment to less affected regions as a result of existing immunity in the population, we 118 also evaluate sensitivity of our predictions to underlying susceptibility in the population, and 119 explore the potential of rapid tests for seropositivity to guide vaccine distribution and avert 120 mortality.

121

122 Methods

123 Data sources: demography, HCWs, and SARS-CoV-2 case distribution

124 Regional population size and age distribution were obtained from the 2018 census (Madagascar

125 Institute of Statistics, INSTAT). The number of healthcare workers in each region was obtained

from UNICEF database for Madagascar. SARS-CoV-2 cases and COVID-19 deaths were obtained from a dashboard (www.covid19mg.org) which compiles data communicated by the Ministry of Health on a daily basis. These data comprise PCR-confirmed cases, deaths per region as well as the number of tests performed nationally. Using these data, we ranked each region based on the size and the age distribution of the population and the number of healthcare workers in the region on the one hand and the situation with regards to the COVID-19 epidemic (officially reported cases and deaths) on the other hand.

133 SARS-CoV-2 transmission model of Madagascar

134 We constructed an age-structured, stochastic SEAIR (susceptible, exposed, asymptomatic 135 infection, symptomatic infection, and removed) transmission model by expanding previous work 136 [16, 17] (see Supplementary figure S1). With this model, we simulated the trajectory of SARS-137 CoV-2 cases in each of the 22 regions of Madagascar under different assumptions about 138 vaccination deployment among the regions (detailed below). For each region, the demography 139 (age-structure and population size) was defined based on INSTAT statistics described above. 140 while contact matrices were based on the social mixing patterns in the Mozambican population 141 [18], since there is no contact matrix data available for Madagascar. We set R0 (the number of 142 new infections per infectious individual in a completely susceptible population) to 2.5 as in [16] 143 and simulated our model for a year. To quantify the burden of infection, we used the age-144 specific mortality risk (infection fatality rate by age) [19, 20], and each vaccination scenario was 145 compared to a 'no vaccination' scenario. We explored a range of different starting proportions of 146 the population susceptible, to reflect potentially varied histories of infection in each region. We 147 initiated the outbreak by seeding 10 individuals in each region.

## 148 Vaccination

149	To con	npare the impact of varying vaccine distribution among the 22 regions of Madagascar on		
150	total mortality, we assumed that the country received a single batch of COVID-19 vaccines that			
151	was sufficient to vaccinate 20% of the population. In our baseline scenario, we assume that			
152	70% of those eligible for vaccination, regardless of age, will accept to be vaccinated with their			
153	full scheduled doses (Transparency International, unpublished). We initially do not assume that			
154	any information regarding previous infection status would be available, i.e. individuals who were			
155	previously infected may be vaccinated. The vaccine is assumed to work uniformly across age			
156	groups and be transmission and infection blocking with an efficacy of 76%, chosen to			
157	approximate the clinical vaccine efficacy against symptomatic infection seen for the ChAdOx1			
158	nCoV-19 (AZD1222) [21, 22]. Finally, we assume that 50% of healthcare workers in each region			
159	would be mandated to vaccinate 20 people a day, based on experience of vaccination programs			
160	in Antananarivo. Vaccination follows an oldest-first strategy where vaccines are administered to			
161	individuals aged 60 years or older first. After all accepting individuals in the eligible group are			
162	vaccinated, individuals from the next (younger) age group are vaccinated and so on until all			
163	available doses are administered.			
164				
165	We then considered five allocation strategies of available doses:			
166	1.	Doses are distributed to regions uniformly (each region receives 4.5% of available		
167		vaccines)		
168	2.	Doses are distributed to regions based on population size (pro-rata),		
169	3.	Doses are allocated based on the distribution of people aged over 60 years between the		
170		regions (age),		

171 4. Doses are distributed to regions based on the number of cases reported (cases),

5. Doses are distributed to regions based on the number of deaths reported (deaths)

173 The number of cases and deaths per region was obtained from the Madagascar COVID-19 174 dashboard (www.covid19mg.org) which collates the reported confirmed cases and deaths per 175 region daily. For each allocation strategy, we then estimated the number of deaths and 176 compared this value to a scenario without vaccination to calculate the number of averted 177 deaths. 178 179 For each allocation strategy, we also varied the number of total doses available nationally (from 180 0 to 26 million covering 0-100% of the population), the vaccine acceptance rate (from 0-100%), 181 the speed of rollout which is equivalent to the number of vaccinators per region (10-100% of 182 healthcare workers in the region) and when the vaccination campaign began (0-200 days). 183 184 To investigate the effect of any potential existing immunity from prior infections, we considered 185 two sets of initial conditions. In the first instance we assumed that 100% of the population was 186 susceptible, all locations included at least 10 infected individuals, and the vaccination campaign 187 would begin soon after the beginning of the simulation (within 10 days). In the second instance, 188 we assumed that there is a baseline level of population-level immunity based on a uniform value 189 for the entire country (0 - 40%) or proportional to reported cases (0-20%, see Supplementary 190 Information). 191 192 To assess the benefit of targeting seronegative individuals through rapid testing, we included 193 age-stratified seroprevalence and simulated different approaches to vaccine distribution.

194

195 Results

Considering either population size, number of health-care workers (Figure 1A,B), number of
reported cases, or numbers of confirmed deaths (Figure 1C,D) provides broadly similar overall

- 198 priority rankings of regions (colours), with the region of Analamanga (AN, which contains the
- 199 capital city, Antananarivo), consistently ranking highest, and the smaller, less densely populated



200 regions (e.g., MK: Melaky) ranking lower.

201

202 Figure 1: Demography, distribution of health care workers, SARS-CoV-2 cases, and 203 deaths across Madagascar. A) The ranking for vaccine distribution based on the population 204 size and number of healthcare workers per region. B) Using the population size and number of 205 healthcare workers, each of the 22 regions was prioritized with regions with a large population 206 size and high number of healthcare workers ordered first (yellow) and those with the smallest 207 population size and number of healthcare workers ranked last (purple). The size of the point 208 corresponds to the proportion of people over 60 years old. C) In contrast, the rankings for 209 regions based on D) the number of confirmed SARS-CoV-2 cases (March 20, 2020 – July 30, 210 2021) based on the number of reported cases and confirmed COVID-19 deaths. Regions would 211 receive doses first if they had the largest reported outbreaks (yellow) and last (purple) if they

212 had few reported cases and deaths. The size of points indicates the number of healthcare workers per capita. 213 214 215 216 217 218 To probe this simple ranking by additionally evaluating the underlying dynamics of infection and 219 vaccine distribution, we simulated five different vaccine distribution scenarios among the 22 220 regions of Madagascar assuming availability of a single batch of vaccines sufficient to vaccinate 221 20% of the population, and distributing doses uniformly (uniform), based on population size 222 (pro-rata), the distribution of older individuals, defined as individuals 60+ years of age (age), 223 reported cases (cases), and deaths (deaths). As expected based on Figure 1, there was a 224 strong correlation between the strategies, and in all scenarios, Analamanga (the region 225 containing the capital city) receives the largest number of vaccines (Figure 2) since it is the 226 highest in all categories considered. We note that this initial prioritization assumes equal starting 227 population immunity, further evaluated below. 228 229



230

Figure 2: The proportion of total doses distributed by region. Assuming that the total vaccine supply is 20% of the entire population, we explored various distribution strategies. The proportion of doses per region is shown based on each prioritization scheme: (A) doses are distributed to regions based on population size (pro-rata), (B) doses are allocated based on the distribution of people aged over 60 years between the regions (age), (C) doses are distributed to regions based on the number of cases reported (cases), (D) doses are distributed to regions based on the number of deaths reported (deaths).

238



240

241 Figure 3 - The estimated reduction in mortality for each vaccine allocation strategy. The 242 reduction in mortality by allocation strategy for a A) stochastic simulations assuming vaccine 243 acceptance of 70%, rollout speed where 50% of health care workers were mandated to 244 vaccinate 20 people a day, start day of 10 days following initial seeding event, and the number 245 of total doses equals 20% of the population; B) by varying the total vaccine supply (other 246 assumptions assumed to be the base scenario, see Materials and Methods); C) using a range 247 of vaccine acceptance rates; D) various roll out speeds; and E) the start date of vaccination. 248 The median and 50 stochastic simulations are shown per sensitivity analysis

249

250

251

252 Overall, under the baseline scenario modeled (Figure 3A, assuming enough doses to immunize 253 20% of the population using a 76% efficacious vaccine with an acceptance rate of 70%, and 254 assume that the population is fully susceptible at the start), any vaccination allocation strategy 255 reduces the estimated number of deaths by 30-40% (Figure 3), and allocating available 256 vaccines between regions based on the population size (pro rata) or the distribution of elderly 257 generally outperform the other strategies (up to 10% more, Figure 3A). This is consistent across 258 a spectrum of vaccine supply, vaccine acceptance, and speed of vaccine rollout (Figure 3B-259 D). The pro rata distribution of vaccines between regions or allocating doses according to the 260 regional distribution of older people outperform distribution according to numbers of cases (or 261 deaths) since all else equal, weighting by numbers of older individuals (which correlates with 262 number of individuals) targets doses towards the most vulnerable [8]. As this quantity correlates 263 with the number of Health Care Workers across regions (Figure 1B), formally modeling dose 264 delivery does not reverse this relationship. However, if the vaccination campaign starts relatively 265 late during the outbreak, all strategies perform equally to reduce mortality compared to a 266 scenario without vaccination (Figure 3E) as the gains are relatively slight at this stage. 267





278 of seropositivity values (distributed uniformly). Vaccinating only susceptible individuals has the greatest reduction in mortality. C) We also investigated if testing at a vaccination site was done 279 280 prior to vaccination with only seronegative individuals vaccinated (dotted line) or no prior 281 information about immune status (solid line). These two scenarios performed similarly. 282 283 284 285 As the impact of previous waves of SARS-CoV-2 (www.covid19mg.org) on population immunity 286 is not completely characterized [23], we evaluate two extreme scenarios: even levels of existing 287 immunity across the country (Figure 4A, solid lines, assuming for simplicity that seropositivity 288 and immunity are equivalent), and levels of immunity defined by reported numbers of cases 289 (Figure 4A dashed lines). As population immunity increases (Figure 4A, x axis) the proportion of 290 deaths averted relative to a scenario of no vaccination declines since fewer vaccines are 291 delivered to individuals who are susceptible; however, the pro-rata and population based 292 allocation still out-perform the other strategies. Allocation by cases and deaths performs much 293 worse if it is assumed that immunity is distributed according to population or deaths, since 294 doses are then targeted predominantly to the regions with lower proportions of susceptible 295 individuals due to existing immunity (Figure 4A, pink and purple dashed lines fall fastest). 296 297 Rapid testing for sero-status (indicative of immunity) is a potential strategy to direct the

deployment of doses towards those who more urgently require vaccination, as they lack prior natural immunity. We explore this by evaluating the percentage of deaths averted if only susceptible individuals are vaccinated (Figure 4B). By contrast with a scenario where vaccine doses are distributed uniformly (Figure 4B, dashed lines), when only susceptible individuals are vaccinated, the percent of deaths averted relative to the no-vaccination case increases with the proportion of the population initially immune (Figure 4B, dotted lines, gains of up to 40%), since

304 vaccines are targeted to those who need them. However, this scenario requires all individuals to 305 know their immune status prior to going to the health centres for vaccination (and the serological 306 tests to be perfect), which is likely to be unrealistic. If, instead, we assume that testing occurs at 307 health centres, thus consuming some proportion of available health care worker time, and 308 slowing down the overall speed of vaccination (although still assuming the tests are perfect). 309 this strategy outperforms distribution regardless of serostatus; however, initial gains in terms of 310 deaths averted drop off as the proportion of the population immune increases (Figure 4C, dotted 311 lines start falling at around 25% of the population immune). The gains eventually even fall below 312 the percent of deaths averted under the uniform distribution of doses once the proportion 313 seropositive is greater than 30%, since so many individuals will be turned away from health 314 centres.

## 315 Discussion

316 High levels of SARS-CoV-2 transmission continues to cause a global public health crisis. Mass 317 vaccination of populations is the most effective strategy to prevent unnecessary morbidity and 318 mortality. However, limited global vaccine supplies compel countries to prioritize among 319 populations, and to do so in the context of an array of logistical constraints (expiration dates, 320 healthcare worker availability, cold chains, etc.). Here, we use a stochastic age-structured 321 model to identify dose allocation strategies that have the potential to minimize COVID-19 related 322 deaths in Madagascar given vaccines provided by the COVAX initiative, and accounting for 323 health care worker distribution across the country.

324

325 At a subnational scale, our results support a regional distribution strategy based on

326 demographic parameters (population size) to allocate available doses of SARS-CoV 2 vaccines

327 in order to achieve the highest reduction in mortality. A distribution policy based on the

328 population size of each region is intuitively appealing as it is equitable and straightforward to

implement. Indeed, pro-rata distribution of critical medicines has been used during a number of
previous health crises. For example, during the 2009 H1N1 pandemic, the US Health and
Human Services Pandemic Influenza Plan recommended that the different states of the USA
receive pandemic vaccines in proportion to the size of its population. Additionally, researchers
found that a simpler pro-rata allocation of antiviral drugs is as effective as optimal strategies
targeting specific high risk groups in each region, and easier to implement [24, 25].

335

336 Given that Madagascar has now experienced multiple waves of infection (www.covid19mg.org) 337 and that estimates of seroprevalence from blood donors in Madagascar show elevated 338 population immunity [23], we also investigated strategies to take previous infection and thus 339 immunity into account. Unsurprisingly, vaccinating only seronegative individuals allows for 340 doses to be reallocated and expand protection to a larger population [8, 26, 27]. However, we 341 note that assessing seropositivity via rapid testing at health facilities could slow the speed of 342 vaccine delivery, which, in situations of high seropositivity, could reduce benefits in terms of 343 mortality reductions. The benefit of additional testing to identify seronegative individuals must be 344 weighed against the logistical challenges of testing, test accuracy [28], and ethical issues for the 345 allocation of doses based on serostatus.

346

347 While allocating doses based on population size reduced mortality more effectively than 348 allocation based on cases (or deaths), large heterogeneity in testing capacity between regions, 349 and reporting issues have likely resulted in underestimates of the true burden of the pandemic. 350 and, importantly, in a possibly spatially biased way. Although our analysis suggests that 351 allocation based on size is robust to a number of assumptions about underlying population 352 immunity, additional investigation, including analysing mortality records available in the capital 353 city of Madagascar [29] and other regions, could improve estimates of transmission and identify 354 communities where the pandemic has been particularly severe. Our analysis assumes similar

355 starting dates for the outbreak in each of the 22 regions and neglects potential subnational 356 heterogeneity in connectivity and contact within them [30]. The latter assumption leads to 357 unrealistically rapid growth in case numbers within each region, such that estimates of 358 reductions in mortality, although comparable, may be overly pessimistic. We also did not take 359 into account time-varying estimates of transmission (Rt) resulting from the introduction of non-360 pharmaceutical interventions in Madagascar, given uncertainty around the magnitude of these 361 effects emerging from data sparseness. Additional analyses that integrate data streams to 362 better bound temporal and spatial variation in transmission could further elucidate how different 363 allocation strategies would perform. Further, we only explored a single dose vaccination 364 strategy, and did not evaluate the impact of various vaccines being distributed simultaneously. 365 since only ChAdOx1-nCOV (Covishield<sup>™</sup>) is currently available in Madagascar. Finally, we 366 assumed that seropositivity and immunity were equivalent, but decision making around the 367 value of rapid tests for vaccine allocation will be shaped by their sensitivity and specificity [28]. 368 which may be population specific [31]) and requires careful evaluation in Madagascar 369

370 To conclude, it is clear that the speed of vaccine deployment will shape the burden of SARS-371 CoV-2. However, logistical limitations associated with healthcare worker numbers lead to 372 inevitable limits associated with speed, complicating allocation across regions. Our analysis 373 probes approaches of dose allocation across regions that most reduce mortality assuming 374 vaccination occurs as fast as possible given these constraints, finding that allocation by 375 population yields consistently high benefits. However, Madagascar, and many other countries 376 worldwide fundamentally require access to more vaccine doses. Vaccine equity is the largest 377 global issue of the present moment.

# 379 Declarations:

### 380 Ethics approval and consent to participate: Not applicable

- 381 **Consent for publication:** Not applicable
- 382 Availability of data and materials: The datasets generated and/or analysed during the current
- 383 study are available in the author's github repository, <u>www.github.com/fidyras/vaccination</u>
- 384 **Competing interests:** The authors declare that they have no competing interests
- 385 Authors Contributions: FR, TR, BLR, CJEM, AW conceived and designed the paper, FR and
- 386 TR wrote and performed the analyses. FR, BLR, CJEM, AW, MVE, BR, AHR, SR, and FMR
- 387 wrote the manuscript.
- 388 **Funding**: FR is supported by Princeton High Meadows Environmental Institute; CJEM is
- 389 supported by the Center for Health and Wellbeing, Princeton University.
- 390 Acknowledgments: Authors would like to thank INSTAT for providing 2018 census data for
- 391 Madagascar, the Ministry of Health for providing data on SARS-CoV2 cases and COVID-19
- 392 deaths in Madagascar. Authors would like to thank Malavika Rajeev for support in building the
- 393 COVID-19 Madagascar dashboard (<u>www.covid19mg.org</u>).

394

395

396

397

398

399

- 401
- 402





405 Figure S1: Modeling framework. The core of the model is similar to that of Roche et al. 2020. 406 The same model has been applied to understanding the covid dynamics and the effectiveness 407 of NPI at a national level in Madagascar (Evans et al. 2020). The stochastic simulation includes 408 eight states: Susceptible (S), Exposed (E), Infected (symptomatic, I), Infected (Asymptomatic, 409 A), and recovered from asymptomatic (U), recovered from symptomatic (R) infected 410 symptomatic individuals who become severely ill (M) and infected symptomatic individuals who 411 die (D) [17]. The population is divided into seven age classes (0-9;10-19;20-29;30-39;40-49;50-412 59: 60+). Susceptible individuals in an age class i  $(S_i)$  can get the infection according to the

413	basal transmission rate ( $meta$ ), the number of infectious (symptomatic and asymptomatic)
414	individuals in each age class, and the contact rate among age classes. Once infected, an
415	individual becomes infectious after an incubation period of 3 days, i.e. at a rate $\varepsilon$ = 1/3 days.
416	Infectious individuals can be symptomatic (I) with a probability of $p$ (assumed to be 40%) or
417	asymptomatic (A) otherwise. Infectious individuals (I and A) can recover at a rate $\sigma$ = 1/5 days.
418	Infectious symptomatic have a probability $\alpha$ to become severely ill and a probability ( $\pi_i$ )
419	dependent on their age class to die from the disease (D).
420	

421 We included vaccination into the model. The daily number of people vaccinated (n) depends on 422 the number of healthcare workers and the total number of individual vaccinated is limited by the 423 acceptance ( $\eta_i$ ). Individuals in the compartment S, E, A, U, and R can be vaccinated. However, 424 vaccinating non-susceptible individuals would lead to vaccine wastage. Thus, we only track the 425 number of susceptibles n<sub>s</sub> that are vaccinated. Without testing, n<sub>s</sub> is drawn from a binomial 426 distribution Binomial(n, S/(S + E + A + U + R)). We consider two scenarios to test for seroprevalence and thus avoid vaccine wastage (see main text). Additionally, vaccination can 427 428 prioritize older individuals or distribute the doses randomly in each age class according to a 429 multinomial distribution where the vector of probabilities are given by the frequency of the 430 individuals in each age-class. Vaccinated individuals gain protection after a lag of 6-days 431 according to the vaccine efficacy (v) which we assumed to be at 76% to approximate the clinical 432 vaccine efficacy against symptomatic infection seen for the ChAdOx1 nCoV-19 (AZD1222). The 433 actual number of people gaining protection is Binomial( $n_{s}, \nu$ ).

### 435 References

- 436 1. Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al. Coronavirus
- 437 Pandemic (COVID-19). Our World in Data. 2020. https://ourworldindata.org/coronavirus.
- 438 Accessed 31 Jul 2021.
- 439 2. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19
- 440 vaccine in low-income countries. Npj Vaccines. 2021;6:54.
- 3. Kupferschmidt K. Unprotected African health workers die as rich countries buy up COVID-19
- 442 vaccines. Science. 2021.
- 443 4. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et
- 444 al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability,
- allocation, and deployment. Lancet. 2021;397 N Engl J Med 383 2020:1023–34.
- 446 5. Metcalf CJE, Tatem A, Bjornstad ON, Lessler J, O'Reilly K, Takahashi S, et al. Transport
- 447 networks and inequities in vaccination: remoteness shapes measles vaccine coverage and
- 448 prospects for elimination across Africa. Epidemiol Infect. 2015;143:1457–66.
- 449 6. Nachega JB, Sam-Agudu NA, Masekela R, Zalm MM van der, Nsanzimana S, Condo J, et al.
- 450 Addressing challenges to rolling out COVID-19 vaccines in African countries. Lancet Global
- 451 Heal. 2021.
- 452 7. Graham M, Winter AK, Ferrari M, Grenfell B, Moss WJ, Azman AS, et al. Measles and the
  453 canonical path to elimination. Science. 2019;364:584–7.
- 454 8. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed
- 455 COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371:916–21.
- 456 9. Castro MC, Singer B. Prioritizing COVID-19 vaccination by age. Proc National Acad Sci.
- 457 2021;118:e2103700118.
- 458 10. Goldstein JR, Cassidy T, Wachter KW. Vaccinating the oldest against COVID-19 saves both
- the most lives and most years of life. Proc National Acad Sci. 2021;118:e2026322118.

- 460 11. Wrigley-Field E, Kiang MV, Riley AR, Barbieri M, Chen Y-H, Duchowny KA, et al.
- 461 Geographically-targeted COVID-19 vaccination is more equitable than age-based thresholds
- 462 alone. Medrxiv. 2021;:2021.03.25.21254272.
- 463 12. Rakotonanahary RJL, Andriambolamanana H, Razafinjato B, Raza-Fanomezanjanahary
- 464 EM, Ramanandraitsiory V, Ralaivavikoa F, et al. Integrating Health Systems and Science to
- 465 Respond to COVID-19 in a Model District of Rural Madagascar. Frontiers Public Heal.
- 466 2021;9:654299.
- 467 13. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2
- 468 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;:1–5.
- 469 14. Saad-Roy CM, Wagner CE, Baker RE, Morris SE, Farrar J, Graham AL, et al. Immune life
- 470 history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science.

471 2020;370:811–8.

- 472 15. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of
- 473 COVID-19 to endemicity. Science. 2021;371:741–5.
- 474 16. Evans MV, Garchitorena A, Rakotonanahary RJL, Drake JM, Andriamihaja B, Rajaonarifara
- 475 E, et al. Reconciling model predictions with low reported cases of COVID-19 in Sub-Saharan
- 476 Africa: insights from Madagascar. Global Health Action. 2020;13:1816044.
- 477 17. Roche B, Garchitorena A, Roiz D. The impact of lockdown strategies targeting age groups
- 478 on the burden of COVID-19 in France. Epidemics-neth. 2020;33:100424.
- 479 18. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact
- 480 surveys and demographic data. Plos Comput Biol. 2017;13:e1005697.
- 481 19. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the
- 482 burden of SARS-CoV-2 in France. Science. 2020;369:208–11.
- 483 20. O'Driscoll M, Santos GRD, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-
- 484 specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020.
- 485 21. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose

- 486 administration and the influence of the timing of the booster dose on immunogenicity and
- 487 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
- 488 Lancet. 2021;397:881–91.
- 489 22. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1
- 490 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an
- 491 exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–62.
- 492 23. Schoenhals M, Rabenindrina N, Rakotondramanga JM, Dussart P, Randremanana R,
- 493 Heraud J-M, et al. SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors
- 494 during the 2020 COVID-19 Epidemic. Ebiomedicine. 2021;68:103419.
- 495 24. Dimitrov N, Goll S, Hupert N, Pourbohloul B, Meyers L. Optimizing Tactics for use of the
- 496 U.S. Antiviral Strategic National Stockpile for Pandemic (H1N1) Influenza, 2009. Plos Curr Influ.
- 497 2009;1:ecurrents.RRN1127.
- 498 25. Araz OM, Galvani A, Meyers LA. Geographic prioritization of distributing pandemic influenza
- 499 vaccines. Health Care Manag Sc. 2012;15:175–87.
- 500 26. Pearson CAB, Clifford S, Pulliam JRC, Eggo RM. Pre-vaccination testing could expand
- 501 coverage of two-dose COVID vaccines. Wellcome Open Res. 2021;6:105.
- 502 27. Tran TN-A, Wikle N, Albert J, Inam H, Strong E, Brinda K, et al. Optimal SARS-CoV-2
- 503 vaccine allocation using real-time seroprevalence estimates in Rhode Island and
- 504 Massachusetts. Medrxiv. 2021;:2021.01.12.21249694.
- 505 28. Takahashi S, Greenhouse B, Rodríguez-Barraquer I. Are Seroprevalence Estimates for
- 506 Severe Acute Respiratory Syndrome Coronavirus 2 Biased? J Infect Dis. 2020;222:jiaa523.
- 507 29. Rasambainarivo F, Rasoanomenjanahary A, Rabarison JH, Ramiadantsoa T, Ratovoson R,
- 508 Randremanana R, et al. Monitoring for outbreak associated excess mortality in an African city:
- 509 Detection limits in Antananarivo, Madagascar. Int J Infect Dis. 2020.
- 510 30. Rice BL, Annapragada A, Baker RE, Bruijning M, Dotse-Gborgbortsi W, Mensah K, et al.
- 511 Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa. Nat Med. 2021;:1–7.

- 512 31. Wiens KE, Mawien PN, Rumunu J, Slater D, Jones FK, Moheed S, et al. Seroprevalence of
- 513 Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020 Volume
- 514 27, Number 6—June 2021 Emerging Infectious Diseases journal CDC. Emerg Infect Dis.
- 515 2021;27:1598-606.









**Figure S1: Modeling framework**. The core of the model is similar to that of Roche et al. 2020. The same model has been applied to understanding the covid dynamics and the effectiveness of NPI at a national level in Madagascar (Evans et al. 2020). The stochastic simulation includes eight states: Susceptible (S), Exposed (E), Infected (symptomatic, I), Infected (Asymptomatic, A), and recovered from asymptomatic (U),recovered from symptomatic (R) infected symptomatic individuals who become severely ill (M) and infected symptomatic individuals who die (D) [17]. The population is divided into seven age classes (0-9;10-19;20-29;30-39;40-49;50-59; 60+) . Susceptible individuals in an age class i (S<sub>i</sub>) can get the infection according to the basal transmission rate ( $\beta$ ), the number of infectious (symptomatic and asymptomatic) individuals in each age class, and the contact rate among age classes. Once infected, an individual becomes infectious after an incubation period of 3 days, i.e. at a rate  $\varepsilon = 1/3$  days. Infectious individuals can be symptomatic (I) with a probability of p (assumed to be 40%) or asymptomatic (A) otherwise. Infectious individuals (I and A) can recover at a rate  $\sigma = 1/5$  days. Infectious symptomatic have a probability  $\alpha$  to become severely ill and a probability ( $\pi_i$ ) dependent on their age class to die from the disease (D).

We included vaccination into the model. The daily number of people vaccinated (*n*) depends on the number of healthcare workers and the total number of individual vaccinated is limited by the acceptance ( $\eta_i$ ). Individuals in the compartment S, E, A, U, and R can be vaccinated. However, vaccinating non-susceptible individuals would lead to vaccine wastage. Thus, we only track the number of susceptibles n<sub>S</sub> that are vaccinated. Without testing, n<sub>S</sub> is drawn from a binomial distribution Binomial(n, S/(S + E + A + U + R). We consider two scenarios to test for seroprevalence and thus avoid vaccine wastage (see main text). Additionally, vaccination can prioritize older individuals or distribute the doses randomly in each age class according to a multinomial distribution where the vector of probabilities are given by the frequency of the individuals in each age-class. Vaccinated individuals gain protection after a lag of 6-days

according to the vaccine efficacy ( $\nu$ ) which we assumed to be at 76% to approximate the clinical vaccine efficacy against symptomatic infection seen for the ChAdOx1 nCoV-19 (AZD1222). The actual number of people gaining protection is Binomial( $n_{s}$ , $\nu$ ).

